Yara Mostafa Soliman
Cairo, Egypt
NCT Number: NCT05707845
The purpose of this study will be investigation of the effect of weight reduction and aerobic exercises on premenstrual syndrome symptoms in obese females.
Looking for future studies?
Notify Me20 year–30 year
Female
Interventional
Not applicable
Cairo, Egypt
both groups (A&B) will take their medical treatment in the form of (NSAIDs) and the study group B will under go a siet plan which will fits the participants. Diet plan extends for 12 weeks in the form of caloric restriction program and each woman in group B will perform aerobic exercise program, in the form of treadmill 3 times/week for 8 weeks for 12 weeks. Each session will take about 30 minutes as the following: 5 minutes warming up exercises by walking on the treadmill by low speed, 20 minutes walking at moderate intensity (70% of the maximal heart rate) and 5 minutes are cooling down by walking on the treadmill by low speed as in warming up.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
Other names: NSAID
weight reduction in the form low caloric diet program for 12 weeks.
Other names: diet program
aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
Other names: aerobic exercise
Time frame: 12 weeks
progesterone level will be checked six to eight days after ovulation start (about day 21st of a 28-day cycle)
Time frame: 12 weeks
Weight and height measurement will be measured while the woman is wearing a thin layer of clothes to calculate the BMI according to the following equation for both groups (A&B):
BMI = weight/height2 (kg/m2).
Time frame: 12 weeks
All women in both groups (A&B) will be evaluated before and after the treatment (12 weeks) to show serum cortisol level. A blood sample was taken from each female in both groups (A & B) before and after the treatment to measure the serum cortisol levels, which could reflect anxiety and pain intensity with decreased cortisol levels indicating decreased pain intensity. The cortisol level was assessed 5 days before the first day of the menstrual cycle preceding the treatment program and 5 days before the first day of the menstrual cycle at the end of treatment program,Blood sample of about 5 cm was drawn from the anticubital vein from all participants by disposable sterile syringe by vein puncture to determine plasma cortisol level. All blood samples were taken at 8-9 am and the norm cortisol level at 9 A.M ranges from 4.3-22.4 ug/dl.
Time frame: 12 weeks
The premenstrual syndrome scale comprised 40 questions with three sub-scales (Physiological, Psychological and Behavioural symptoms). This 5-point Likert- type scale consisting of 40 items. The measurements on the scale are set according to the following scoring system: the response Never was scored as "1", rarely as "2", sometimes as "3", very often as "4" and always as "5" points, the total score obtained from the sub-scales established the "PMSS total score." The scale's lowest score is 40 and highest score is 200. If the scale's total score reached 80 points or above, this indicates the occurrence of PMS. Increases in the scores indicate an increase in PMS severity.
Time frame: 12 weeks
Waist circumference was measured at the narrowest point between xipho-sternum and the iliac crest at the end of a gentle expiration; hip circumference was measured at the maximum circumference at the level of femoral trochanter. Then, waist/hip ratio was calculated by dividing waist circumference on hip circumference. All measurements were taken for all patients in both groups (A&B), while the patient was in the standing position, before starting and after the end of the treatment course.
Cairo University
Other
Effect of Weight Reduction and Aerobic Exercise on Premenstrual Syndrome Symptoms in Obese Females
Acronym: PMS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05811130
Behavior, Menstruation Disturbances
Pécs, Baranya, Hungary
View Trial DetailsNCT05692479
Behavior, Menstruation Disturbances
Niğde, Turkey (Türkiye)
View Trial DetailsNCT05428800
Behavior, Menstruation Disturbances
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT05290181
Behavior, Menstruation Disturbances
Aydin, Söke, Turkey (Türkiye)
View Trial Details